Total Payments
$112,099
2024 Payments
$1,767
Companies
22
Transactions
146
Medicare Patients
412
Medicare Billing
$85,473
Payment Breakdown by Category
Other$53,654 (47.9%)
Consulting$43,783 (39.1%)
Travel$10,700 (9.5%)
Food & Beverage$3,891 (3.5%)
Education$71.71 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,783 | 18 | 39.1% |
| Honoraria | $34,100 | 13 | 30.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $11,773 | 6 | 10.5% |
| Travel and Lodging | $10,700 | 46 | 9.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,781 | 8 | 6.9% |
| Food and Beverage | $3,891 | 51 | 3.5% |
| Education | $71.71 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. | $38,725 | 46 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $30,018 | 27 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $13,528 | 19 | $0 (2023) |
| Amgen Inc. | $5,184 | 9 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $4,608 | 7 | $0 (2021) |
| RECORDATI_RARE_DISEASES_INC. | $4,000 | 2 | $0 (2022) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $3,075 | 1 | $0 (2022) |
| Celgene Corporation | $2,821 | 4 | $0 (2022) |
| PFIZER INC. | $2,460 | 4 | $0 (2022) |
| Rigel Pharmaceuticals, Inc. | $1,743 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,767 | 7 | SERVIER PHARMACEUTICALS LLC ($1,130) |
| 2023 | $13,747 | 20 | SERVIER PHARMACEUTICALS LLC ($7,858) |
| 2022 | $19,023 | 20 | SERVIER PHARMACEUTICALS LLC ($8,473) |
| 2021 | $15,856 | 15 | Servier Pharmaceuticals LLC ($12,557) |
| 2020 | $14,113 | 15 | Agios Pharmaceuticals, Inc. ($9,942) |
| 2019 | $40,090 | 54 | Agios Pharmaceuticals, Inc. ($22,983) |
| 2018 | $7,298 | 13 | Agios Pharmaceuticals, Inc. ($4,670) |
| 2017 | $205.46 | 2 | Seattle Genetics, Inc. ($205.46) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $110.18 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Education | In-kind items and services | $19.47 | General |
| Category: Genetically Defined Disease | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $563.47 | General |
| 05/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Oncology | ||||||
| 05/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: Oncology | ||||||
| 02/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,020.00 | General |
| Category: Oncology | ||||||
| 02/09/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: BioOncology | ||||||
| 12/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $38.99 | General |
| Category: Oncology | ||||||
| 09/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,290.00 | General |
| Category: Oncology | ||||||
| 04/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $599.80 | General |
| Category: Oncology | ||||||
| 04/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $343.23 | General |
| Category: Oncology | ||||||
| 04/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $148.21 | General |
| Category: Oncology | ||||||
| 04/21/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $136.50 | General |
| Category: Oncology | ||||||
| 04/03/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 03/30/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $340.00 | General |
| Category: Oncology | ||||||
| 03/24/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Consulting Fee | Cash or cash equivalent | $4,237.50 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | Cash or cash equivalent | $707.35 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | In-kind items and services | $647.19 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | Cash or cash equivalent | $44.53 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | Cash or cash equivalent | $33.47 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | Cash or cash equivalent | $32.00 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Travel and Lodging | Cash or cash equivalent | $28.43 | General |
| Category: Genetic Disease | ||||||
| 03/01/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | Cash or cash equivalent | $27.10 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 99 | 263 | $166,832 | $27,729 |
| 2022 | 4 | 67 | 153 | $92,568 | $13,744 |
| 2021 | 5 | 115 | 196 | $79,851 | $16,833 |
| 2020 | 5 | 131 | 351 | $92,855 | $27,167 |
Total Patients
412
Total Services
963
Medicare Billing
$85,473
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 157 | $86,036 | $15,650 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 65 | $51,090 | $7,642 | 15.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $12,342 | $1,872 | 15.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 12 | $12,768 | $1,751 | 13.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 12 | $4,596 | $813.48 | 17.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 81 | $44,388 | $6,760 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 29 | $22,794 | $3,442 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 31 | $16,554 | $2,319 | 14.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $8,832 | $1,223 | 13.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 87 | $35,409 | $7,643 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 55 | $23,376 | $4,505 | 19.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $9,980 | $2,006 | 20.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 18 | 18 | $6,578 | $1,576 | 24.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 19 | $4,508 | $1,103 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 167 | $46,403 | $14,992 | 32.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 21 | 80 | $16,510 | $4,973 | 30.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 68 | $20,466 | $4,372 | 21.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 20 | 21 | $6,174 | $1,887 | 30.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 14 | 15 | $3,302 | $943.23 | 28.6% |
About John Quigley
John Quigley is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912010323.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Quigley has received a total of $112,099 in payments from pharmaceutical and medical device companies, with $1,767 received in 2024. These payments were reported across 146 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($43,783).
As a Medicare-enrolled provider, Quigley has provided services to 412 Medicare beneficiaries, totaling 963 services with total Medicare billing of $85,473. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Chicago, IL
- Active Since 08/17/2006
- Last Updated 05/20/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912010323
Products in Payments
- TIBSOVO (Drug) $51,554
- Tibsovo (Drug) $8,988
- OXLUMO (Drug) $5,792
- GIVLAARI (Drug) $5,096
- PANHEMATIN (Drug) $4,000
- Blincyto (Biological) $3,726
- ONCASPAR (Drug) $3,713
- SOLIRIS (Drug) $3,608
- Fedratinib (Drug) $2,797
- MYLOTARG (Biological) $2,400
- Tavalisse (Drug) $1,743
- Vonjo (Drug) $1,725
- DARZALEX (Biological) $1,483
- Doptelet (Drug) $1,451
- ADCETRIS (Biological) $377.29
- GIVLARRI (Drug) $100.26
- Kyprolis (Biological) $78.20
- KEYTRUDA (Biological) $61.67
- BOSULIF (Drug) $57.78
- SARCLISA (Biological) $38.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678